anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-07-17. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
== Services == The Instituto Universitario de Restauración del Patrimonio is divided into two areas: the area of intervention in the Pictorial and Sculptural Heritage and the area of intervention in the Architectural Heritage, and a Training and Dissemination area. The area of intervention in the pictorial and sculptural heritage operates in both basic research and applied research in seeking to acquire new knowledge to develop new products, techniques, processes, methods and systems that improve existing ones. The area of intervention in the Pictorial and Sculptural Heritage consist in restoration workshops:
=== Kinetic binding === Kinetic binding experiments differ from saturation and competition experiments in that they are not done at equilibrium. Instead, they measure the course of binding of the radioligand during the experiment as well as the dissociation to determine calculation of the Kd, and rate constants of binding and dissociation. Kinetic binding experiments are also called dissociation binding experiments and can help evaluate the interaction of the radioligand and the targeted receptor.
Insulin injections of a mixture of regular (or rapid) and intermediate acting insulin are performed two times a day, or to improve overnight glucose, mixed in the morning to cover breakfast and lunch, but with regular (or rapid) acting insulin alone for dinner and intermediate acting insulin at bedtime (instead of being mixed in at dinner). Meals are scheduled to match the anticipated peaks in the insulin profiles. The target range for blood glucose levels is higher than is desired in the intensive regimen. Frequent measurements of blood glucose levels were not used.
Zinc Fact Sheet from the U.S. National Institutes of Health History & Etymology of Zinc Statistics and Information from the U.S. Geological Survey Archived October 8, 2011, at the Wayback Machine Reducing Agents > Zinc American Zinc Association Information about the uses and properties of zinc. ISZB International Society for Zinc Biology, founded in 2008. An international, nonprofit organization bringing together scientists working on the biological actions of zinc. Zinc-UK Founded in 2010 to bring together scientists in the United Kingdom working on zinc. Zinc at The Periodic Table of Videos (University of Nottingham) ZincBind – a database of biological zinc binding sites.
Incubation, which regulates temperature for chick development, usually begins after the last egg has been laid. In monogamous species incubation duties are often shared, whereas in polygamous species one parent is wholly responsible for incubation. Warmth from parents passes to the eggs through brood patches, areas of bare skin on the abdomen or breast of the incubating birds. Incubation can be an energetically demanding process; adult albatrosses, for instance, lose as much as 83 grams (2.9 oz) of body weight per day of incubation. The warmth for the incubation of the eggs of megapodes comes from the sun, decaying vegetation or volcanic sources. Incubation periods range from 10 days (in woodpeckers, cuckoos and passerine birds) to over 80 days (in albatrosses and kiwis). The diversity of characteristics of birds is great, sometimes even in closely related species. Several avian characteristics are compared in the table below.
Sources: en.wikipedia.org
A diphenylamine (DPA) indicator will confirm the presence of DNA. This procedure involves chemical hydrolysis of DNA: when heated (e.g. ≥95 °C) in acid, the reaction requires a deoxyribose sugar and therefore is specific for DNA. Under these conditions, the 2-deoxyribose is converted to w-hydroxylevulinyl aldehyde, which reacts with the compound, diphenylamine, to produce a blue-colored compound. DNA concentration can be determined by measuring the intensity of absorbance of the solution at the 600 nm with a spectrophotometer and comparing to a standard curve of known DNA concentrations. Measuring the intensity of absorbance of the DNA solution at wavelengths 260 nm and 280 nm is used as a measure of DNA purity. DNA can be quantified by cutting the DNA with a restriction enzyme, running it on an agarose gel, staining with ethidium bromide (EtBr) or a different stain and comparing the intensity of the DNA with a DNA marker of known concentration. Using the Southern blot technique, this quantified DNA can be isolated and examined further using PCR and RFLP analysis. These procedures allow differentiation of the repeated sequences within the genome. It is these techniques which forensic scientists use for comparison, identification, and analysis.
reactive bond A chemical bond between atoms which, in a particular context, is relatively unstable and therefore easily broken or invaded by other chemical species or radicals; e.g. the double bond in ethylene (CH2=CH2) is highly reactive in the presence of other ethylene molecules, leading to a polymerization reaction that forms polyethylene.
=== Primary === The eRF1 is composed of a polypeptide chain of amino acids in the shape of the letter Y. The protein is composed of 3 major domains: a stem and 2 branches. Each domain has a specific purpose and distinct folding pattern which allows the protein to function properly. While each domain is unique, they all contain the basic structure of an α-β sandwich class, which is essentially a β sheet core surrounded by α helices. Domain 1, sometimes referred to as the N domain, is constructed from a β-sheet core with 4 strands surrounded by 2 α-helices (α2 and α3). The subunits α2 and α3 coil and bind to form a hairpin structure that contains the NIKS motif, YxxCxxxF motif, and the GTS loop. These sites are hypothesized to be the primary appendage in stop codon recognition. Additionally the N-terminus is located in Domain 1, which interacts with Domain 3 in-order to maintain protein stability. Domain 3, sometimes referred to as the C domain, contains the C-terminus of the polypeptide. Additionally, the structure and function of Domain 3, referred to as the M domain, is the least known as optical limitations hinder further research. Domain 2 consists of an α-β sandwich, with one of the outer strands of the sandwich containing no secondary structure. The primary amino acid section allows the GGQ site to form. The folded structure of eRF1 is essentially mimicking the structure of a tRNA molecule. This ensures that the eRF1 machinery fits into the aminoacyl site of the ribosome.
A mass spectrometer consists of 5 components: sample inlet, ion source (or ionizer), mass analyzer, detector, data system. Each component can be varied somewhat independently from the other components, and the full mass spectrometer itself can be included as a component in an analysis pipeline, allowing great flexibility. The sample inlet prepares the sample to be analyzed in a suitable state. The ion source takes samples from the sample inlet, converts a portion of the sample into a stream of ions, and outputs it to the mass analyzer. There is a wide variety of ionization techniques, depending on the phase (solid, liquid, gas) of the sample and the efficiency of various ionization mechanisms for the unknown species. An extraction system removes ions from the sample, which are then targeted into the mass analyzer. The mass analyzer takes an input stream of ions and separates ("analyzes") its constituent ions according to their m/z, the mass-to-charge ratio. The detector measures the value of an indicator quantity and thus provides data for calculating the abundances of each ion present. Some detectors also give spatial information, e.g., a multichannel plate.
Sources: en.wikipedia.org
==== Ebola treatment ==== In 2014, the FDA added an Ebola treatment being developed by Canadian pharmaceutical company Tekmira to the Fast Track program, but halted the phase 1 trials in July pending the receipt of more information about how the drug works. This was widely viewed as increasingly important in the face of a major outbreak of the disease in West Africa that began in late March 2014 and ended in June 2016.
==== Syndiotactic polystyrene ==== Ziegler–Natta polymerization can produce an ordered syndiotactic polystyrene with the phenyl groups positioned on alternating sides of the hydrocarbon backbone. This form is highly crystalline with a Tm (melting point) of 270 °C (518 °F). Syndiotactic polystyrene resin is currently produced under the trade name XAREC by Idemitsu corporation, who use a metallocene catalyst for the polymerisation reaction.
=== Adhesion to zirconia === Tensile bond strength to zirconia of ethanol solutions that contains MDP were measured. MDP showed high bond strengths to zirconia. Tensile bond strengths of MDP containing resin composites to zirconia ceramic were statistically significantly higher when compared with the bond strength of the conventional Bis-GMA resin composite which contains no adhesive monomer. The mechanisms of coordination between MDP and zirconium oxide were demonstrated by using 1H and 31P magic angle spinning nuclear magnetic resonance (NMR) and two dimensional 1H → 31P heteronuclear correlation NMR. The spectra indicated three possible models as mechanisms of interaction of MDP with zirconia.
Enthesitis, wherein there is inflammation of the entheses, the sites where tendons or ligaments insert into the bone. It is associated with HLA B27 arthropathies such as ankylosing spondylitis, psoriatic arthritis, and reactive arthritis. Apophysitis, inflammation of the bony attachment, generally associated with overuse among growing children.
== Function == The main purpose of chondronectin is to allow chondrocytes and collagen II substrates to bond together. When bound, if forms a complex structure called an extracellular scaffold, which helps support the surrounding cells because of bioactive molecule diversity, which allows for chondrocytes to be anchored, mechanical forces to be bared, and maintaining physiological homeostasis. In order for chondronectin to be able to assist in binding within this complex as efficiently as possible, they must interact with a cartilage proteoglycan monomer. If there is a inhibitor that prevents synthesis of endogenous proteoglycans, along with beta-xylosides, it fully prevents chondrocytes from attaching via chondronectins. When cartilage cells attach chondronectin help keep the cells positioned close to important collagen and proteoglycan materials within the extracellular matrix. This allows the cells to support the framework by maintaining surrounding cartilage components. Without attachment, chondrocytes become less effective at preserving the tissue around them. Chondronectin keeps the cartilage framework strong enough to handle daily joint pressure. It helps cartilage deal with the stress caused by regular movement and compression. Since joints face constant wear, cell bonds must stay stable to help prevent tissue damage. This protein plays a key role in keeping cartilage durable and properly supported. Studies indicate that weak adhesive interaction inside cartilage matrix can gradually reduce the integrity to cartilage.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.